We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

LumiraDx

LumiraDx develops, manufactures and commercializes industry-leading point of care (POC) diagnostic platforms that use... read more Featured Products: More products

Download Mobile App





LumiraDx Introduces Its Innovative and Disruptive LumiraDx Platform at AACC Clinical Lab Expo

By LabMedica International staff writers
Posted on 27 Sep 2021
Print article
Image: LumiraDx Platform and Test Strip (Photo courtesy of LumiraDx)
Image: LumiraDx Platform and Test Strip (Photo courtesy of LumiraDx)

LumiraDx (London, UK) introduced the LumiraDx Platform, its innovative, disruptive solution designed to deliver lab-comparable performance to transform community care, at the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo.

AACC's annual meeting which was held this year in Atlanta on September 26-30 is the world's largest lab medicine conference with nearly 20,000 participants from more than 100 countries.

The LumiraDx Platform is an innovative, next generation point of care diagnostic system that combines a small, portable instrument, advanced low cost test strip and seamless secure digital connectivity to the Cloud and hospital IT systems. The LumiraDx Platform and tests are designed on the same principles as lab analyzer systems, to deliver accurate results compared to laboratory reference assays across a number of parameters, in a portable, easy-to-use point of care solution. Easy and intuitive to use, it requires only basic training and is designed to be affordable and accessible at the point of care

LumiraDx has developed a high sensitivity antigen test for COVID-19 on the LumiraDx Platform. The LumiraDx COVID-19 antigen test has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) and achieved CE Mark. The LumiraDx Platform and COVID-19 antigen tests are also available in Japan and Brazil and being rolled out in more than 60 countries globally. The LumiraDx Platform menu also includes point of care tests for COVID-19 Antibody, INR and D-Dimer - with high levels of accuracy comparable to central lab-based tests - all of which have achieved CE Mark and are commercially available in Europe. The Platform is designed to go wherever the patient is, whether this is in a hospital, medical office, pharmacy, or in other non-traditional settings such as schools or airports.

Related Links:
LumiraDx

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
New
Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
New
3α-Diol G Assay
3α-Diol G ELISA Kit
New
Bordetella Pertussis Molecular Assay
Alethia Pertussis

Print article
ADLM

Channels

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Pathology

view channel
Image: The study examined the influence of pre-analytical conditions on cell-free microRNA stability in blood plasma samples (Photo courtesy of 123RF)

Pre-Analytical Conditions Influence Cell-Free MicroRNA Stability in Blood Plasma Samples

Scientists worldwide are working to enhance the quality of diagnostics and prognosis for various diseases, including cancer, by analyzing different body fluids such as blood, urine, and saliva.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.